Cerebral cortical blood flow in rabbits during parabolic flights (hypergravity and microgravity).
We studied the effect of gravity on cerebral cortical blood flow (CBF), mean arterial blood pressure (BPa) and heart rate in six rabbits exposed to parabolic flights. The CBF was obtained using a laser-Doppler probe fixed on to a cranial window. Before weightlessness, the animals were exposed to chest-to-back directed acceleration (1.8-2.0 g). The CBF values were expressed as a percentage of CBFo (mean CBF during 60 s before the 1st parabola). Propranolol (1 mg x kg[-1] i.v.) was given after the 11th parabola and pentobarbital (12-15 mg x kg[-1] i.v.) after the 16th parabola. Before the administration of the drugs, CBF increased (P < 0.01) during hypergravity [i.e. maximal CBF 151 (SD 64)% CBFo. Simultaneously BPa increased [maximal BPa, 119 (SD 11) mmHg (P < 0.01)]. At the onset of weightlessness, CBF and BPa reached maximal values [194 (SD 96)% CBFo (P < 0.01) and 127 (SD 19) mmHg, (P < 0.01) respectively]. The microgravity-induced increase in CBF was transient since CBF returned to its baseline value after 8 (SD 2) s of microgravity. After propranolol administration, CBF was not statistically different during hypergravity but an elevation of CBF was still observed in weightlessness. The increases in CBF and BPa also persisted during weightlessness after pentobarbital administration. These data would indicate that CBF of nonanesthetized rabbits increases during the first seconds of weightlessness and demonstrate the involvement of rapid active regulatory mechanisms since CBF returned to control values within 8 (SD 2) s. We concluded that this elevation in blood flow was not related to stress because it persisted after the administration of propranolol and pentobarbital.
Florence
G
G
Institut de Médecine Aérospatiale du Service de Santé des Armées, Département de Physiologie Gravitationnelle, Brétigny sur Orge, France.
Lemenn
M
M
Desert
S
S
Bourron
F
F
Serra
A
A
Bonnier
R
R
Blanquie
J P
JP
Charbonné
R
R
Seylaz
J
J
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002540:Cerebral Cortex / Q000098:blood supply* / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D018471:Hypergravity / Q000009:adverse effects*; D017078:Laser-Doppler Flowmetry; D008297:Male; D010424:Pentobarbital / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D013312:Stress, Physiological / Q000503:physiopathology; D014893:Weightlessness / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D010424:Pentobarbital